2024-03-29T07:19:03Zhttp://repisalud.isciii.es/oai/requestoai:repisalud.isciii.es:20.500.12105/139392023-10-09T13:01:06Zcom_20.500.12105_15322com_20.500.12105_2051com_20.500.12105_2053com_20.500.12105_2052col_20.500.12105_16982col_20.500.12105_16981col_20.500.12105_16978col_20.500.12105_16963col_20.500.12105_16938col_20.500.12105_2054
00925njm 22002777a 4500
dc
Berenguer, Juan
author
Jarrin-Vera, Inmaculada
author
Pérez-Latorre, Leire
author
Hontañón, Víctor
author
Vivancos, María J
author
Navarro, Jordi
author
Téllez, María Jesús
author
Guardiola, Josep M
author
Iribarren, José A
author
Rivero-Juárez, Antonio
author
Márquez, Manuel
author
Artero, Arturo
author
Morano, Luis
author
Santos, Ignacio
author
Moreno, Javier
author
Fariñas, María C
author
Galindo, María J
author
Hernando, María A
author
Montero, Marta
author
Cifuentes, Carmen
author
Domingo, Pere
author
Sanz, José
author
Domíngez, Lourdes
author
Ferrero, Oscar L
author
De la Fuente, Belén
author
Rodríguez, Carmen
author
Reus, Sergio
author
Hernández-Quero, José
author
Gaspar, Gabriel
author
Pérez-Martínez, Laura
author
García, Coral
author
Force, Lluis
author
Veloso, Sergio
author
Losa, Juan E
author
Vilaró, Josep
author
Bernal, Enrique
author
Arponen, Sari
author
Ortí, Amat J
author
Chocarro, Ángel
author
Teira, Ramón
author
Alonso, Gerardo
author
Silvariño, Rafael
author
Vegas, Ana
author
Geijo, Paloma
author
Bisbe, Josep
author
Esteban, Herminia
author
González-García, Juan
author
GeSIDA 8514 Study Group
author
2018
Background: We assessed the prevalence of antibodies against hepatitis C virus (HCV-Abs) and active HCV infection in patients infected with human immunodeficiency virus (HIV) in Spain in 2016 and compared the results with those of similar studies performed in 2002, 2009, and 2015. Methods: The study was performed in 43 centers during October-November 2016. The sample was estimated for an accuracy of 2% and selected by proportional allocation and simple random sampling. During 2016, criteria for therapy based on direct-acting antiviral agents (DAA) were at least significant liver fibrosis, severe extrahepatic manifestations of HCV, and high risk of HCV transmissibility. Results: The reference population and the sample size were 38904 and 1588 patients, respectively. The prevalence of HCV-Abs in 2002, 2009, 2015, and 2016 was 60.8%, 50.2%, 37.7%, and 34.6%, respectively (P trend <.001, from 2002 to 2015). The prevalence of active HCV in 2002, 2009, 2015, and 2016 was 54.0%, 34.0%, 22.1%, and 11.7%, respectively (P trend <.001). The anti-HCV treatment uptake in 2002, 2009, 2015, and 2016 was 23.0%, 48.0%, 59.3%, and 74.7%, respectively (P trend <.001). In 2016, HCV-related cirrhosis was present in 7.6% of all HIV-infected individuals, 15.0% of patients with active HCV, and 31.5% of patients who cleared HCV after anti-HCV therapy. Conclusions: Our findings suggest that with universal access to DAA-based therapy and continued efforts in prevention and screening, it will be possible to eliminate active HCV among HIV-infected individuals in Spain in the short term. However, the burden of HCV-related cirrhosis will continue to be significant among HIV-infected individuals.
Open Forum Infect Dis. 2018 12;5(1):ofx258.
2328-8957
http://hdl.handle.net/20.500.12105/13939
29354658
10.1093/ofid/ofx258
Open Forum Infectious Diseases
Coinfection/epidemiology
Hepatitis C/drug therapy/epidemiology
HIV infection/epidemiology
Spain/epidemiology
Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant